Biocon receives approval from SAHPRA for Tacrolimus Capsule

Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients

Biocon inks agreement for Ozempic commercialization in Brazil with Biomm

Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market

Biocon's European partner Zentiva receives approval from UK MHRA for Liraglutide

The company had earlier announced about the approval received from the MHRA for Liraglutide

Biocon to obtain approval for diabetes drug, Liraglutide in UK

Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus

Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr

Both organisations enter into a long- term collaboration to expand patient access in India

Indranil Sen, CFO, Biocon resigned

Sen spent a decade with Biocon and held various key roles,

Biocon Biologics secures Canada market entry date for YESAFILI

This agreement paves the way for the introduction of YESAFILI into the Canadian market

Biocon appoints Vishal Nayyar as Head – SCM and Amit Kaptain as Head Commercials - API

Biocon Biologics secures US market entry date for Bmab 1200

The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA

Biocon included in S&P Global Sustainability Yearbook 2024

Sustainability is integral to Biocon's business purpose